MM‐302, a novel HER2‐targeted, PEGylated liposomal doxorubicin with anti‐HER2 antibody attached on the liposomal surface, was developed to treat HER2 Positive Breast Cancer, but failed to meet its primary endpoint of progression‐free survival.92, 93. The gene discussed is ERBB2; the disease is breast cancer.